Could This Seattle Pot Stock SOAR as Legal Weed Market Expands?
Fifteen states plus the District of Columbia now permit the recreational use of cannabis and Congress is on track to decriminalize marijuana possession on the federal level. As a result, the North American cannabis market is expected to TRIPLE in size from $30 billion to $100 billion by the year 2027 – and one Seattle manufacturer is poised to cash in!
Details in Brand-New Special Report!
Jay T. Flatley, insider at Zymergen
Jay T. Flatley Insider Alerts

Get notified the next time Jay T. Flatley buys or sells Zymergen stock. Enter your email address below to get our daily insider buying and selling report.

Jay T. Flatley Insider Information

CEO of Zymergen
Jay served as CEO of Illumina, a cutting-edge company in the human health space, for 17 years, and as its Executive Chair, and later Chairman of the Board, until 2021. During his tenure as CEO Jay took Illumina from $1.3 million in sales in 2000 to $2.2 billion in 2015.

In addition to being Chairman and Acting CEO of Zymergen, Jay serves as a member of the Boards of Denali Therapeutics Inc. and Coherent Inc., is an advisory board member for U.C. San Diego’s Moore Cancer Center and serves on the Board of Trustees for The Salk Institute for Biological Studies. Mr. Flatley holds a BSc and MSc (Hons) from Stanford University, along with a BA from Claremont McKenna College.

What is Jay T. Flatley's net worth?

The estimated net worth of Jay T. Flatley is at least $1.41 million as of May 18th, 2021. Mr. Flatley owns 148,933 shares of Zymergen stock worth more than $1,413,374 as of November 30th. This net worth evaluation does not reflect any other investments that Mr. Flatley may own. Learn More.

How do I contact Jay T. Flatley?

The corporate mailing address for Mr. Flatley and other Zymergen executives is , , . Zymergen can also be reached via phone at 415-801-8073 and via email at [email protected]

Has Jay T. Flatley been buying or selling shares of Zymergen?

During the past quarter, Jay T. Flatley has bought $1,000,000.00 of Zymergen stock. Most recently, on Wednesday, November 17th, Jay T. Flatley bought 100,000 shares of Zymergen stock. The stock was acquired at an average cost of $10.00 per share, with a total value of $1,000,000.00.

Are insiders buying or selling shares of Zymergen?

In the last twelve months, Zymergen insiders bought shares 1 times. They purchased a total of 100,000 shares worth more than $1,000,000.00. The most recent insider tranaction occured on November, 17th when CEO Jay T Flatley bought 100,000 shares worth more than $1,000,000.00.

Information on this page was last updated on 11/17/2021.

Jay T. Flatley Insider Trading History at Zymergen

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/17/2021Buy100,000$10.00$1,000,000.00View SEC Filing Icon  
See Full Table

Jay T. Flatley Buying and Selling Activity at Zymergen

This chart shows Jay T Flatley's buying and selling at Zymergen by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Zymergen Company Overview

Zymergen logo
Zymergen Inc. designs, engineers, and optimizes microbes for industrial applications in United States, Asia, and Europe. The company has a platform that treats the genome as a search space, to identify genetic changes that improve the economics for its customers' bio-based products for a range of industries, including chemicals and materials, agriculture, and pharmaceuticals. Zymergen's platform is used to discover novel molecules used to enable unique material properties. The company was incorporated in 2013 and is based in Emeryville, California.
Read More

Today's Range

Now: $9.49
Low: $9.13
High: $9.79

50 Day Range

MA: $11.16
Low: $8.14
High: $14.19

2 Week Range

Now: $9.49
Low: $7.85
High: $52.00

Volume

2,051,785 shs

Average Volume

1,647,187 shs

Market Capitalization

$971.79 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
Is this Seattle Penny Pot Stock a Potential Blockbuster?
A small, rapidly expanding Seattle cannabis company is gaining attention from investors. Founded by two cannabis veterans, the company has increased sales 8-fold since inception. Now selling for less than $1 per share, this is an opportunity to acquire thousands of shares – a potential windfall.
Get Free Report on #1 Cannabis Pick for 2021